Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LXRX with free AI briefings, catalyst countdowns, and dilution alerts.

LXRX · LEXICON PHARMACEUTICALS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$183.2M Cash on Hand
63.6mo Cash Runway
Follow LXRX by email Get an email when LXRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LXRX, unsubscribe in one click. Privacy

📣 What LXRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sotagliflozin (LX4211)
FDA approved May 2023 · Inpefa
Type 1 Diabetes (T1D) Phase 3 · NCT07211802 Not yet recruiting
Telotristat Etiprate Carcinoid Syndrome Phase 3 · NCT02026063 Completed
Metformin Type 2 Diabetes Mellitus Phase 3 · NCT03066830 Completed
Sulfonylurea Antidiabetic Agent Type 2 Diabetes Mellitus Phase 3 · NCT03066830 Completed
Oral Antidiabetes Drugs (OADs) Type 2 Diabetes Mellitus Phase 3 · NCT03285594 Completed
LX9211 Diabetic Peripheral Neuropathic Pain Phase 2 · NCT06203002 Completed
Nab-paclitaxel Locally Advanced Unresectable Pancreatic Adenocarcinoma Phase 2 · NCT03910387 Completed
Octreotide LAR Depot Carcinoid Syndrome Phase 2 · NCT00853047 Completed
Volagidemab Type 1 Diabetes Phase 1/2 · NCT05696366 Active not recruiting
LX7101 (0.125%) Primary Open-angle Glaucoma Phase 1/2 · NCT01528111 Completed
Treatment C Digoxin + 400 mg LX4211… Healthy Phase 1 · NCT02300350 Completed
Treatment C (rosuvastatin + 400 mg LX4211… Healthy Phase 1 · NCT02300363 Completed
Treatment B LX4211 Healthy Phase 1 · NCT02300350 Completed
Treatment B (LX4211) Healthy Phase 1 · NCT02300363 Completed
Treatment A digoxin Healthy Phase 1 · NCT02300350 Completed
Treatment A (rosuvastatin) Healthy Phase 1 · NCT02300363 Completed

Also used in these trials (approved or third-party drugs, not LXRX's own candidates): Empagliflozin, Glimepiride, Insulin Glargine, Telotristat Ethyl, Gemcitabine Hydrochloride, Octreotide Acetate, Midazolam Hydrochloride, Famotidine, Omeprazole, Apixaban.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LXRX holds $183.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.6M/quarter from operations, an estimated runway of 63.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 32 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LXRX files for a raise →

👥 Who Owns LXRX

Insiders 52.3% Institutions (202 holders) 47.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Participations S.a r.l. Artal
Director, 10% owner
Insider 175,156,062 39.34% 2026-04-30
FMR LLC Institution (13G, 5%+) 66,743,390 14.99% 2026-09-30
Raymond Debbane
Director · +43,478 options
Insider 51,750,221 11.62% 2026-06-03
Avicenna Life Sci Master Fund LP
Director, 10% owner
Insider 1,538,462 0.35% 2026-02-02
Invus Global Management, LLC
Director, 10% owner
Insider 1,385,689 0.31% 2026-02-02
Brian T Crum
SVP, General Counsel & Secr. · +789,887 options
Insider 428,802 0.10% 2026-02-28
Philippe Amouyal
Director · +43,478 options
Insider 374,486 0.08% 2026-06-03
Michael Exton
Chief Executive Officer, Director · +2.30M options
Insider 328,496 0.07% 2026-11-06
Craig B Granowitz
SVP, Chief Medical Officer · +924,440 options
Insider 323,430 0.07% 2026-02-28
Christopher J Sobecki
Director · +43,478 options
Insider 293,177 0.07% 2026-06-03
Wendy McDermott
SVP, Human Resources · +664,087 options
Insider 277,945 0.06% 2026-02-28
Sam L Barker
Director · +43,478 options
Insider 213,771 0.05% 2026-06-03

Share count 445,234,571 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LXRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LXRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.